Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes

Molecular Cancer Therapeutics

Volumn 13, Issue 12, 2014, Pages 2784-2792

  Hasanali, Zainul S ^a   Epner, Elliot M ^b   Feith, David J ^c   Loughran, Thomas P ^c   Sample, Clare E ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; SMALL INTERFERING RNA; VORINOSTAT; ANTIBODY CONJUGATE; CAC10-VCMMAE; HYDROXAMIC ACID; MESSENGER RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; LYMPHOCYTE; NATURAL KILLER T CELL; PROTEIN EXPRESSION; T LYMPHOCYTE; ANTAGONISTS AND INHIBITORS; CELL MEMBRANE; DRUG ANTAGONISM; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ANTIGENS, CD30; CELL LINE, TUMOR; CELL MEMBRANE; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROXAMIC ACIDS; IMMUNOCONJUGATES; LYMPHOCYTES; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84917694588     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0593     Document Type: Article

References (25)

1. Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, et al. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol 2012;30:3921-3.
2. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. The Oncologist 2007;12:1247-52.
3. DeWoskin VA, Million RP. The epigenetics pipeline. Nat Rev Drug Discov 2013;12:661-2.
4. Sassoon I, Blanc V. Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol Biol 2013;1045:1-27.
5. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25:84-90.
6. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631-7.
7. Newland AM, Li JX, Wasco LE, Aziz MT, Lowe DK. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate. Pharmacotherapy 2013;33:93-104.
8. Li JY, Horwitz S, Moskowitz A, Myskowski PL, Pulitzer M, Querfeld C. Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. Cancer Manag Res 2012;4:75-89.
9. Wozniak MB, Piris MA. Cutaneous T-cell lymphoma: two faces of the same coin. J Invest Dermatol 2010;130:348-51.
10. Vahdat AM, Reiners KS, Simhadri VL, Eichenauer DA, Boll B, Chalaris A, et al. TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species. Leukemia 2010;24:51-7.
11. Gregory CD, Rowe M, Rickinson AB. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol 1990;71:1481-95.
12. Fischer P, Nacheva E, Mason DY, Sherrington PD, Hoyle C, Hayhoe FG, et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 1988;72:234-40.
13. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 1996;24:406-15.
14. Lahm HW, Stein S. Characterization of recombinant human interleu-kin- 2 with micromethods. J Chromatog 1985;326:357-61.
15. Nagata S, Ise T, Onda M, Nakamura K, Ho M, Raubitschek A, et al. Cell membrane-specifi c epitopes on CD30: Potentially superior targets for immunotherapy. Proc Natl Acad Sci U S A 2005;102:7946-51.
16. Hasanali Z, Sharma K, Spurgeon S, Okada C, Stuart A, Shimko S, et al. Combined epigenetic and immunotherapy produces dramatic responses in 100% of newly diagnosed mantle cell lymphoma patients. Cancer Res 2013;73:8s (suppl; abstr LB-140).
17. Yao YL, Yang WM, Seto E. Regulation of transcription factor YY1 by acetylation and deacetylation. Mol Cell Biol 2001;21:5979-91.
18. Franchina M, Woo AJ, Dods J, Karimi M, Ho D, Watanabe T, et al. The CD30 gene promoter microsatellite binds transcription factor Yin Yang 1 (YY1) and shows genetic instability in anaplastic large cell lymphoma. J Pathol 2008;214:65-74.
19. Croager EJ, Gout AM, Abraham LJ. Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene. Am J Pathol 2000;156:1723-31.
20. Sharman JP, Oki Y, Advani RH, Bello CM, Winter JN, Yang Y, et al. A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive Non-Hodgkin lymphomas: Interim results in patients with DLBCL and other B-Cell lymphomas. Blood 2013;122:848.
21. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012;90:85-94.
22. Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005;125:1045-52.
23. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, upregulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 2002;99:11700-5.
24. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31.
25. Froese P, Lemke H, Gerdes J, Havsteen B, Schwarting R, Hansen H, et al. Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines. J Immunol 1987;139:2081-7.